INNO-206 is a novel conjugate of doxorubicin that binds covalently to albumin, the most abundant protein in blood plasma, and is circulated throughout the body.
Patients received three different dose levels of INNO-206 to determine its maximum tolerated dose in the trial.
The maximum tolerated dose of INNO-206 that delivers a doxorubicin equivalent of 3½ times the standard doxorubicin dose administered to sarcoma patients was determined.
Five patients completed four cycles with INNO-206 at the maximum tolerated dose, of which one showed a partial tumor response and four patients have stable disease.